Related references
Note: Only part of the references are listed.HIGH RISK HUMAN PAPILLOMAVIRUS GENOTYPING IN CLINICAL SAMPLES: EVALUATION OF DIFFERENT COMMERCIAL TESTS
F. Paolini et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2011)
Prevalence and Risk Factors of Human Papillomavirus (HPV) Infection in Southern Chinese Women - A Population-Based Study
Stephanie Si Liu et al.
PLOS ONE (2011)
A Population-based Study on the Risks of Cervical Lesion and Human Papillomavirus Infection among Women in Beijing, People's Republic of China
Changdong Li et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Evaluation of a Newly Developed GenoArray Human Papillomavirus (HPV) Genotyping Assay and Comparison with the Roche Linear Array HPV Genotyping Assay
Stephanie S. Liu et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Prevalence and Genotype Distribution of Cervical Human Papillomavirus Infection in Macao
Yuk-Ching Yip et al.
JOURNAL OF MEDICAL VIROLOGY (2010)
Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China
Fang Hui Zhao et al.
LANCET ONCOLOGY (2010)
Prevalence and risk profile of cervical human papillomavirus infection in Zhejiang Province, southeast China: a population-based study
Jing Ye et al.
VIROLOGY JOURNAL (2010)
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
Susanne K. Kjaer et al.
CANCER PREVENTION RESEARCH (2009)
Human Papillomavirus (HPV) Vaccines: Limited Cross-Protection against Additional HPV Types
Rolando Herrero
JOURNAL OF INFECTIOUS DISEASES (2009)
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial
Nubia Munoz et al.
LANCET (2009)
A review of human carcinogens-Part B: biological agents
Veronique Bouvard et al.
LANCET ONCOLOGY (2009)
Epidemiology of Mucosal Human Papillomavirus Infection and Associated Diseases
Helen Trottier et al.
PUBLIC HEALTH GENOMICS (2009)
Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province
Min Lin et al.
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY (2008)
Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries
Sue J. Goldie et al.
VACCINE (2008)
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology:: a meta-analysis
Silvia de Sanjose et al.
LANCET INFECTIOUS DISEASES (2007)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The epidemiology of human papillomavirus infection and cervical cancer
F. Xavier Bosch et al.
DISEASE MARKERS (2007)
Human papillomavirus infection in Shenyang City, People's Republic of China: a population-based study
L. K. Li et al.
BRITISH JOURNAL OF CANCER (2006)
Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study
M. Dai et al.
BRITISH JOURNAL OF CANCER (2006)
The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population
M. Inoue et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Worldwide distribution of human papillomavirus types in cytologically normal women in the international Agency for Research on Cancer HPV prevalence surveys:: a pooled analysis
GM Clifford et al.
LANCET (2005)
Epidemiologic classification of human papillomavirus types associated with cervical cancer
N Muñoz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Host and viral genetics and risk of cervical cancer: a review
A Hildesheim et al.
VIRUS RESEARCH (2002)
Share Paper
